Preprint Concept Paper Version 5 This version is not peer-reviewed

Implantable Systems for Continuous Liquorpheresis and CSF Replacement

Version 2 : Received: 20 December 2016 / Approved: 21 December 2016 / Online: 21 December 2016 (10:12:13 CET)
Version 5 : Received: 30 January 2017 / Approved: 30 January 2017 / Online: 30 January 2017 (14:22:03 CET)

How to cite: Menendez Gonzalez, M. Implantable Systems for Continuous Liquorpheresis and CSF Replacement. Preprints 2016, 2016120105 (doi: 10.20944/preprints201612.0105.v5). Menendez Gonzalez, M. Implantable Systems for Continuous Liquorpheresis and CSF Replacement. Preprints 2016, 2016120105 (doi: 10.20944/preprints201612.0105.v5).

Abstract

Liquorpheresis (CSF filtration) comprises a therapeutical approach that has been proposed to treat several neurological conditions where antibodies, inflammatory mediators or abnormal peptides are the cause or play an important role in the pathogenesis of the disease. CSF replacement may be an alternative approach not explored so far. Here, we review previous experiences in the use of liquorpheresis in autoimmune and degenerative neurological diseases. Then we describe previous developments and provide some new technical innovations in order to design bidirectional CSF shunting systems. These systems can be complemented either with a deposit of artificial CSF or with a CSF filter, allowing CSF replacement or liquorpheresis respectively. Both options would lead to mechanical dilution of the patient’s CSF.

Subject Areas

csf; shunt; filtration; neurodegenerative; neuroimmunology; alzheimer; parkinson; guillain-barre; device; ventriculo-peritoneal shunt

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.